Pharsight

Drug name - Amyvid

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8506929 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

US7687052 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

CN101522624A AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

CN101522624B AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

IN288160B AVID RADIOPHARMS INC Styrylpyridine Compounds
Mar, 2027

(4 years from now)

IN200807219P1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

EP2363392B1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

EP2363392A1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

EP1999109A2 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Jan, 2028

(5 years from now)

EP1999109B1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Jan, 2028

(5 years from now)

Drugs and Companies using FLORBETAPIR F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10ML (13.5-51mCi/ML) SOLUTION;INTRAVENOUS Discontinued
10-30ML (13.5-51mCi/ML) SOLUTION;INTRAVENOUS Prescription
10-50ML (13.5-51mCi/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.